Objectives Referral of patients from dermatology to rheumatology practices due to psoriasis is unnecessary delayed. Many times musculoskeletal symptoms are the first reason for consultation. We aimed to estimate the proportion of ARP-PsA (arthralgia with risk to progression) defined by patients with arthralgia and the presence of psoriasis and/or a family history. Also, identify clinical, laboratory, and imaging prognostic factors of PsA progression within the ARP-PsA group over a one-year follow-up period. Methods Patients were included in a comprehensive arthralgia evaluation program, with the ARP-PsA criteria defined as arthralgia with Pso and/or a family history of Pso, not referred from dermatology. Baseline characteristics were analyzed, and the progression to PsA at one year was assessed. Multivariate analysis identified predictor features for progression. Results Of the 1419 patients, 8.4% met ARP-PsA criteria, and 29% of this subgroup developed PsA at one year. Baseline differences between those who developed PsA and those who did not included family history, Pso duration, pain severity, joint count, and imaging findings (X-ray and ultrasound). Multivariate analysis revealed the predictive significance of a combination of Pso plus family history of psoriasis disease, synovitis by Power Doppler ultrasound, ultrasound enthesopathy findings, and low tender joint count. Conclusion The frequency of patients ARP-PsA was 8.4%, of whom 29% developed PsA at 1-year. The main predictor variables for this progression were identified.

中文翻译：

---

有进展为银屑病关节炎风险的关节痛：临床评估和超声作为预后因素的作用


目的 由于银屑病，患者从皮肤科转诊到风湿病科是不必要的延迟。很多时候，肌肉骨骼症状是咨询的第一个原因。我们旨在估计关节痛患者定义的 ARP-PsA （有进展风险的关节痛） 的比例，以及银屑病的存在和/或家族史。此外，在一年的随访期内确定 ARP-PsA 组内 PsA 进展的临床、实验室和影像学预后因素。方法 将患者纳入全面的关节痛评估计划，ARP-PsA 标准定义为关节痛伴有 Pso 和/或 Pso 家族史，而不是来自皮肤病学。分析基线特征，并评估 1 年时进展为 PsA。多变量分析确定了进展的预测因素特征。结果 1419 例患者中，8.4% 符合 ARP-PsA 标准，该亚组中 29% 在 1 年时发生 PsA。发生 PsA 的患者与未发生 PsA 的患者之间的基线差异包括家族史、Pso 持续时间、疼痛严重程度、关节计数和影像学检查结果（X 射线和超声）。多变量分析揭示了 Pso 加上银屑病家族史、Power Doppler 超声滑膜炎、超声附着点病发现和低压痛关节计数的组合的预测意义。结论 患者 ARP-PsA 发生率为 8.4%，其中 29% 在 1 年时发生 PsA。确定了这种进展的主要预测变量。